Human milk oligosaccharides (HMOs)
are one of the important ingredients
in human milk, which have attracted great interest due to their beneficial
effect on the health of newborns. The large-scale production of HMOs
has been researched using engineered microbial routes due to the availability,
safety, and low cost of host strains. In addition, the development
of molecular biology technology and metabolic engineering has promoted
the effectiveness of HMOs production. According to current reports,
2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL),
lacto-N-tetraose (LNT), lacto-N-neotetraose
(LNnT), 3′-sialyllactose (3′-SL), 6′-sialyllactose
(6′-SL), and some fucosylated HMOs with complex structures
have been produced via the engineered microbial route,
with 2′-FL having been produced the most. However, due to the
uncertainty of metabolic patterns, the selection of host strains has
certain limitations. Aside from that, the expression of appropriate
glycosyltransferase in microbes is key to the synthesis of different
HMOs. Therefore, finding a safe and efficient glycosyltransferase
has to be addressed when using engineered microbial pathways. In this
review, the latest research on the production of HMOs using engineered
microbial routes is reported. The selection of host strains and adapting
different metabolic pathways helped researchers designing engineered
microbial routes that are more conducive to HMOs production.